"The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart "...
Do not administer DEFINITY® to patients with known or suspected:
- Right-to-left, bi-directional, or transient right-to-left cardiac shunts,
- Hypersensitivity to perflutren [see WARNINGS AND PRECAUTIONS].
Do not administer DEFINITY® by intra-arterial injection.
Last reviewed on RxList: 8/31/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Definity Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.